Update on Chronic Hepatitis B

Journal for Nurse Practitioners

Volumn 6, Issue 8, 2010, Pages 631-639

  Rustgi, Vinod ^a   Carriero, Damaris ^b   Bachtold, Michelle ^c   Zeldin, Gillian ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Metropolitan Liver and Gastroenterology Center   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic HBV infection; Cirrhosis; Hepatitis B; Hepatocellular carcinoma; Interferon

Indexed keywords

EID: 77956524344     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2010.01.004     Document Type: Article

References (57)

1. Lavanchy D Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
2. Weissberg JL, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984, 101(5):613-616.
3. Fattovich G, Bortolotti F, Donato F Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008, 48:335-352.
4. de Jongh FE, Janssen HL, de Man RA, et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630-1635.
5. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994, 21:656-666.
6. Ohata K, Hamasaki K, Toriyama K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004, 19:670-675.
7. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
8. Imperial JC Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol 1999 May, 14(Suppl):S1-S5.
9. Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991, 114:629-634.
10. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996, 334:1422-1427.
11. Lok AS, Heathcote EJ, Hoofnagle JH Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001, 120:1828-1853.
12. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005, 25:472-489.
13. Lok AS, McMahon BJ Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861.
14. McQuillan GM, Coleman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14-18.
15. Margolis HS, Coleman PJ, Brown RE, et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995, 274:1201-1208.
16. Wasley A, Grytdal S, Gallagher K Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008, 57:1-24.
17. Centers for Disease Control and Prevention Hepatitis B Fact Sheet. Last update Accessed July 2008. http://www.cdc.gov/ncidod/diseases/hepatitis/b/fact.htm.
18. Rawls RA, Vega KJ Viral hepatitis in minority America. J Clin Gastroenterol 2005, 39:144-151.
19. Fattovich G, Stroffolini T, Zagni I, Donato F Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):S35-S50.
20. Michielsen PP, Francque SM, van Dongen JL Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 2005, 3:27.
21. Centers for Disease Control and Prevention Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40(RR-13);1-19. Publication date: 11/22/1991 Cited June 28, 2010. http://wonder.cdc.gov/wonder/prevguid/m0033405/m0033405.asp.
22. Centers for Disease Control and Prevention Disease burden from hepatitis A, B, and C in the United States. MMWR 2003, 51(53).
23. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005, 97:265-272.
24. Lin CL, Kao JH Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008, 15:137-145.
25. Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007, 133:1452-1457.
26. Chang JJ, Lewin SR Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 2007, 85:16-23.
27. Villeneuve JP The natural history of chronic hepatitis B virus infection. J Clin Virol 2005, 34(Suppl 1):S139-S142.
28. Yuen M-F, Yuan H-J, Wong DK-H, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54:1610-1614.
29. Iloeje UH, Yang H-I, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
30. Chen CJ, Iloeje UH, Yang HI Long-term outcomes in hepatitis B: the REVEALHBV study. Clin Liver Dis 2007, 11:797-816. viii.
31. Perrillo R Hepatitis B virus replication x time equals trouble. Gastroenterology 2006, 130:989-991.
32. Gambarin-Gelwan M Hepatitis B in pregnancy. Clin Liver Dis 2007, 11:945-963.
33. McMahon BJ Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006, 101(Suppl 1):S7-12.
34. Lok ASF, McMahon BJ AASLD Practice Guidelines. Chronic Hepatitis B. Hepatology 2007, 45:507-539.
35. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
36. Nguyen MH, Keeffe EB Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009, 16:149-155.
37. Ayoub WS, Keeffe EB Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008, 28(2):167-177.
38. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008, 8:167-178.
39. Mohanty SR, Kupfer SS, Khiani V Treatment of chronic hepatitis B. Nature Clin Pract Gastro Hepatol 2006, 3:446-458.
40. Gish RG, Perrillo RP, Jacobson IM Customizing the management of chronic hepatitis B virus infection. Semin Liver Dis 2007, 27(Suppl 1):9-17.
41. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastro Hepatol 2007, 5:890-897.
42. Buster EHCJ, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007, 46:388-394.
43. Cooksley WG Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004, 24(Suppl 1):45-53.
44. Puoti M, Airoldi M, Bruno R Hepatitis B virus co-infectino in HIV. AIDS Rev 2002, 4:27-35.
45. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
46. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
47. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
48. Keam SJ Telbivudine. Drugs 2007, 67(13):1917-1929.
49. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588.
50. Liaw Y-F, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
51. Gaeta GB, Stornaiuolo G Therapy of chronic hepatitis B: focus on telbivudine. Dig Liver Dis 2007, 39(Suppl 3):S372-S378.
52. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009 Jul, 51(1):11-20. Epub 2009 Feb 12.
53. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008, 359:2442-2455.
54. Heathcote H, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 103). EASL 2008 (unpublished data).
55. Patel SM, Zembower TR, Palella F, et al. Early onset of tenofovir-induced renal failure: case report and review of the literature. Sci World J 2007, 7:1140-1148.
56. Zimmerman RK, Ruben FL, Ahwesh ER Hepatitis B virus infection, hepatitis B vaccine, and hepatitis B immune globulin. J Fam Pract 1997, 45:295-315.
57. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(RR-16):1-33.